NZ603271A - Anti-erbb3 antibodies - Google Patents

Anti-erbb3 antibodies

Info

Publication number
NZ603271A
NZ603271A NZ603271A NZ60327111A NZ603271A NZ 603271 A NZ603271 A NZ 603271A NZ 603271 A NZ603271 A NZ 603271A NZ 60327111 A NZ60327111 A NZ 60327111A NZ 603271 A NZ603271 A NZ 603271A
Authority
NZ
New Zealand
Prior art keywords
erbb3 antibodies
antibody
disclosed
erbb3
antibodies
Prior art date
Application number
NZ603271A
Other languages
English (en)
Inventor
Sylvie Vincent
William M Winston Jr
Fang Wang
Solly Weiler
Kristan Meetze
Lyne Breault
Steve Bottega
Ting Chen
Michael Deprima
Christina Fleet
Steven Tyler
Jin-Kyeung Woo
Jeno Gyuris
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Publication of NZ603271A publication Critical patent/NZ603271A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ603271A 2010-04-09 2011-04-08 Anti-erbb3 antibodies NZ603271A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32271210P 2010-04-09 2010-04-09
PCT/US2011/031829 WO2011136911A2 (en) 2010-04-09 2011-04-08 Anti-erbb3 antibodies

Publications (1)

Publication Number Publication Date
NZ603271A true NZ603271A (en) 2014-05-30

Family

ID=44120965

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ603271A NZ603271A (en) 2010-04-09 2011-04-08 Anti-erbb3 antibodies

Country Status (18)

Country Link
US (6) US8481687B2 (enExample)
EP (1) EP2566895B1 (enExample)
JP (1) JP5906233B2 (enExample)
KR (1) KR101764453B1 (enExample)
CN (2) CN105968206B (enExample)
AR (1) AR080873A1 (enExample)
AU (1) AU2011245636B2 (enExample)
BR (1) BR112012025730B1 (enExample)
CA (1) CA2795799C (enExample)
ES (1) ES2566602T3 (enExample)
IL (1) IL222272B (enExample)
MX (1) MX343227B (enExample)
NZ (1) NZ603271A (enExample)
PH (1) PH12012502022B1 (enExample)
RU (1) RU2568051C2 (enExample)
SG (1) SG184452A1 (enExample)
WO (1) WO2011136911A2 (enExample)
ZA (1) ZA201208290B (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
EP2132312B1 (en) 2007-03-27 2016-01-27 Sea Lane Biotechnologies,llc. Constructs and libraries comprising antibody surrogate light chain sequences
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
DK2516469T3 (en) 2009-12-22 2016-05-02 Roche Glycart Ag ANTI-HER3 antibodies and uses thereof
WO2011136911A2 (en) 2010-04-09 2011-11-03 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
PL2606070T3 (pl) 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
ES2692379T3 (es) 2010-11-01 2018-12-03 Symphogen A/S Anticuerpos anti-HER3 y composiciones
ITRM20100577A1 (it) * 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
JP2014508782A (ja) 2011-03-11 2014-04-10 メリマック ファーマシューティカルズ インコーポレーティッド ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用
CN103429262A (zh) 2011-03-15 2013-12-04 梅里麦克制药股份有限公司 克服对erbb途径抑制剂的抗性
HRP20170713T1 (hr) 2011-04-19 2017-07-14 Merrimack Pharmaceuticals, Inc. Bispecifično anti-igf-1r i anti-erbb3 antitijelo
EP2736928B1 (en) * 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
JP6271432B2 (ja) 2011-09-30 2018-01-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ＥｒｂＢ３抗体およびその使用
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
US9828635B2 (en) 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
MX350957B (es) * 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
KR20140099315A (ko) * 2011-12-05 2014-08-11 노파르티스 아게 Her3의 도메인 iii 및 도메인 iv에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
EP2788382A2 (en) * 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
WO2013096828A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
WO2014012165A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
MX2015011712A (es) 2013-03-06 2016-04-04 Merrimack Pharmaceuticals Inc Anticerpos biespecificos fc en fila anti-c-met.
EP2821071A1 (en) 2013-07-04 2015-01-07 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for breast cancer treatment
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10538591B2 (en) * 2014-03-10 2020-01-21 The Brigham And Women's Hospital, Inc. Anti-fibulin-3 antibodies and uses thereof
WO2015143126A1 (en) 2014-03-19 2015-09-24 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
SG11201607258SA (en) * 2014-04-10 2016-10-28 Obi Pharma Inc Antibodies, pharmaceutical compositions and uses thereof
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
CA2959775A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
CA2959716A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
KR102390359B1 (ko) * 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
CN104861068B (zh) * 2015-01-23 2020-11-17 中国人民解放军军事科学院军事医学研究院 一种全人源抗her3抗体及其治疗相关疾病的用途
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CA3000531A1 (en) * 2015-10-07 2017-04-13 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
US20180346571A1 (en) * 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
HK1258375A1 (zh) 2015-11-24 2019-11-08 Onk Therapeutics Limited 人源化抗-cll-1抗体
KR101746152B1 (ko) * 2015-12-07 2017-06-13 주식회사 이수앱지스 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
AU2017235450A1 (en) 2016-03-15 2018-08-16 Merrimack Pharmaceuticals, Inc. Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
HUE058657T2 (hu) * 2016-06-23 2022-09-28 Jiangsu Hengrui Medicine Co Lag-3 antitest, antigénkötõ fragmentuma és gyógyszerészeti alkalmazása
CN106692969B (zh) * 2016-12-08 2021-08-10 北海康成（北京）医药科技有限公司 抗erbb3抗体及其用途
CA3047833A1 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
KR20240074000A (ko) 2017-02-28 2024-05-27 다이이찌 산쿄 가부시키가이샤 항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
EP3600421A4 (en) * 2017-03-23 2021-01-06 The Trustees of The University of Pennsylvania ANTI-C5A ANTIBODIES AND USES OF THEM
CN113683698B (zh) * 2017-06-22 2023-03-31 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
CA3070100A1 (en) * 2017-07-17 2019-01-24 Janssen Biotech, Inc. Antigen binding regions against fibronectin type iii domains and methods of using the same
JP2020532991A (ja) 2017-09-07 2020-11-19 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド プログラム細胞死タンパク質１に対する抗体
WO2019076277A1 (zh) * 2017-10-17 2019-04-25 江苏恒瑞医药股份有限公司 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗ＰＨＦ－Ｔａｕ抗體及其用途
GB201804094D0 (en) 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
BR112020015999A2 (pt) 2018-04-06 2020-12-15 Dana-Farber Cancer Institute, Inc. Kir3dl3 como um receptor de hhla2, anticorpos anti-hhla2 e usos dos mesmos
WO2020059772A1 (ja) 2018-09-20 2020-03-26 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
WO2020163646A1 (en) * 2019-02-08 2020-08-13 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
WO2020214957A1 (en) * 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
CN118465272B (zh) * 2019-12-04 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
US20230075244A1 (en) * 2020-02-20 2023-03-09 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
WO2021188631A1 (en) * 2020-03-18 2021-09-23 Kindred Biosciences, Inc. Anti-il4 receptor antibodies for veterinary use
WO2022144025A1 (zh) * 2021-01-04 2022-07-07 上海翰森生物医药科技有限公司 一种抗erbb3受体的抗体或其抗原结合片段及其医药用途
WO2023147470A2 (en) 2022-01-28 2023-08-03 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
CN114940714B (zh) * 2022-05-20 2023-06-16 湖南师范大学 肝癌标志物soat1单克隆抗体制备及其应用
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CN115109161B (zh) * 2022-06-28 2023-08-11 广东赛尔生物科技有限公司 含有间充质干细胞的减肥药物组合物
EP4637821A1 (en) * 2022-12-23 2025-10-29 Actinium Pharmaceuticals, Inc. Her3 radioimmunotherapy for the treatment of solid cancers
CN118005795B (zh) * 2024-04-09 2024-06-28 天津旷博同生生物技术有限公司 一种抗人cd64抗体及应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
PT896586E (pt) * 1996-03-27 2007-01-31 Genentech Inc Anticorpos de erbb3
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US20070009972A1 (en) 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
HRP20131113T1 (hr) * 2007-02-16 2014-01-17 Merrimack Pharmaceuticals, Inc. Protutijela protiv erbb3 i njihova uporaba
US8362215B2 (en) 2009-04-29 2013-01-29 Trellis Bioscience, Llc Antibodies immunoreactive with heregulin-coupled HER3
EP2467164A2 (en) 2009-08-21 2012-06-27 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of erbb3 and uses thereof
EP2486052A4 (en) 2009-10-09 2013-05-01 Merck Sharp & Dohme GENERATION, LABELING AND USE OF ANTI-HER3 ANTIBODIES
DK2516469T3 (en) 2009-12-22 2016-05-02 Roche Glycart Ag ANTI-HER3 antibodies and uses thereof
WO2011136911A2 (en) 2010-04-09 2011-11-03 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
ES2632486T3 (es) * 2010-10-18 2017-09-13 Mediapharma S.R.L. Anticuerpo de unión a ErbB3
US9828635B2 (en) * 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies

Also Published As

Publication number Publication date
CA2795799A1 (en) 2011-11-03
CN102884085A (zh) 2013-01-16
IL222272A0 (en) 2012-12-31
AR080873A1 (es) 2012-05-16
US20160264679A1 (en) 2016-09-15
ZA201208290B (en) 2013-07-31
KR20130043106A (ko) 2013-04-29
CN105968206A (zh) 2016-09-28
US9598498B2 (en) 2017-03-21
US20130330772A1 (en) 2013-12-12
BR112012025730B1 (pt) 2020-12-08
KR101764453B1 (ko) 2017-08-02
PH12012502022B1 (en) 2019-03-08
US10494441B2 (en) 2019-12-03
MX2012011718A (es) 2012-12-17
RU2568051C2 (ru) 2015-11-10
US20230365710A1 (en) 2023-11-16
US20180030149A1 (en) 2018-02-01
JP5906233B2 (ja) 2016-04-20
EP2566895B1 (en) 2015-12-30
US11680108B2 (en) 2023-06-20
US20110256154A1 (en) 2011-10-20
US8481687B2 (en) 2013-07-09
CN105968206B (zh) 2020-01-17
AU2011245636A2 (en) 2012-11-29
RU2012147591A (ru) 2014-05-20
CA2795799C (en) 2018-09-25
BR112012025730A2 (pt) 2017-01-10
PH12012502022A1 (en) 2013-01-21
JP2013523166A (ja) 2013-06-17
BR112012025730A8 (pt) 2017-05-23
US9228021B2 (en) 2016-01-05
SG184452A1 (en) 2012-11-29
ES2566602T3 (es) 2016-04-14
CN102884085B (zh) 2016-08-03
IL222272B (en) 2018-04-30
EP2566895A2 (en) 2013-03-13
US20200299406A1 (en) 2020-09-24
WO2011136911A3 (en) 2012-03-08
WO2011136911A2 (en) 2011-11-03
US12486332B2 (en) 2025-12-02
MX343227B (es) 2016-10-28
HK1178184A1 (zh) 2013-09-06
AU2011245636B2 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
NZ603271A (en) Anti-erbb3 antibodies
EP4417263A3 (en) Cd3 binding antibodies
WO2019224716A8 (en) Antibodies specific for gucy2c and uses thereof
HK1200468A1 (en) Anti-erbb3 antibodies and uses thereof
EP4233909A3 (en) Anti-cmet antibody drug conjugates and methods for their use
PH12014502419A1 (en) Specific binding proteins and uses thereof
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
TN2015000396A1 (en) Antibody drug conjugates
MY173839A (en) Cd37-binding molecules and immunoconjugates thereof
AU2015347015A8 (en) Antibody drug conjugates
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
AU2011338480A8 (en) Humanized antibodies to LIV-1 and use of same to treat cancer
PH12012502215A1 (en) Anti-fgfr2 antibodies
WO2014163714A3 (en) Antibody drug conjugates
WO2016059602A3 (en) Combination therapy with anti-her3 antibodies to treat cancer
PH12013500337A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2013004979A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
WO2011041319A3 (en) Specific binding proteins and uses thereof
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
IN2014DN09717A (enExample)
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
WO2011153243A3 (en) Anti-angiogenesis therapy for treating gastric cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2016 BY IN-LEGAL LIMITED

Effective date: 20151002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2017 BY COMPUTER PACKAGES INC

Effective date: 20160318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180818

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2020 BY IN-LEGAL LIMITED

Effective date: 20190924

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2024 BY COMPUTER PACKAGES INC

Effective date: 20230317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250417